Genexine Inc (095700) - Total Assets
Based on the latest financial reports, Genexine Inc (095700) holds total assets worth ₩366.23 Billion KRW (≈ $248.19 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Genexine Inc shareholders equity for net asset value and shareholders' equity analysis.
Genexine Inc - Total Assets Trend (2009–2024)
This chart illustrates how Genexine Inc's total assets have evolved over time, based on quarterly financial data.
Genexine Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Genexine Inc's total assets of ₩366.23 Billion consist of 13.6% current assets and 86.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩1.16 Billion | 0.3% |
| Accounts Receivable | ₩4.78 Billion | 1.4% |
| Inventory | ₩3.12 Billion | 0.9% |
| Property, Plant & Equipment | ₩118.94 Billion | 34.5% |
| Intangible Assets | ₩28.74 Billion | 8.3% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Genexine Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Genexine Inc (095700) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genexine Inc's current assets represent 13.6% of total assets in 2024, a decrease from 65.4% in 2009.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2024, down from 4.1% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is property, plant & equipment at 34.5% of total assets.
Genexine Inc Competitors by Total Assets
Key competitors of Genexine Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Genexine Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.58 | 0.98 | 0.51 |
| Quick Ratio | 0.58 | 0.92 | 0.51 |
| Cash Ratio | 0.00 | 0.04 | 0.00 |
| Working Capital | ₩-27.53 Billion | ₩-1.04 Billion | ₩-19.57 Billion |
Genexine Inc - Advanced Valuation Insights
This section examines the relationship between Genexine Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.77 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -8.4% |
| Total Assets | ₩345.04 Billion |
| Market Capitalization | $167.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genexine Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genexine Inc's assets decreased by 8.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genexine Inc (2009–2024)
The table below shows the annual total assets of Genexine Inc from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩345.04 Billion ≈ $233.83 Million |
-8.38% |
| 2023-12-31 | ₩376.59 Billion ≈ $255.21 Million |
-3.14% |
| 2022-12-31 | ₩388.78 Billion ≈ $263.47 Million |
-38.95% |
| 2021-12-31 | ₩636.86 Billion ≈ $431.59 Million |
+6.69% |
| 2020-12-31 | ₩596.91 Billion ≈ $404.52 Million |
+66.65% |
| 2019-12-31 | ₩358.18 Billion ≈ $242.73 Million |
-4.44% |
| 2018-12-31 | ₩374.81 Billion ≈ $254.00 Million |
+166.33% |
| 2017-12-31 | ₩140.73 Billion ≈ $95.37 Million |
-29.18% |
| 2016-12-31 | ₩198.71 Billion ≈ $134.66 Million |
+39.84% |
| 2015-12-31 | ₩142.10 Billion ≈ $96.30 Million |
+124.21% |
| 2012-12-31 | ₩63.38 Billion ≈ $42.95 Million |
+61.73% |
| 2011-12-31 | ₩39.19 Billion ≈ $26.56 Million |
+4.02% |
| 2010-12-31 | ₩37.67 Billion ≈ $25.53 Million |
-11.94% |
| 2009-12-31 | ₩42.78 Billion ≈ $28.99 Million |
-- |
About Genexine Inc
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses… Read more